We evaluated the effect of buprenorphine, a mixed agonist for -opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors, in neuropathic rats, using the paw pressure test. Buprenorphine, administered i.p. at 50, but not 20, g/kg, exhibited naloxone-reversible analgesic activity in naïve rats. In contrast, buprenorphine at 0.5 -20 g/kg produced a naloxone-sensitive antihyperalgesic effect in the L5 spinal nerve-injured neuropathic rats. Intrathecal injection of [N-Phe 1 ]nociceptin(1-13)NH 2 , a NOP-receptor antagonist, reversed the effect of buprenorphine in neuropathic rats, but not in naïve rats. Together, buprenorphine suppresses neuropathic hyperalgesia by activating NOP and opioid receptors, suggesting its therapeutic usefulness in treatment of neuropathic pain.
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Short Communication
Buprenorphine is a partial -opioid receptor agonist with antagonistic activity toward -opioid receptors (1) . Buprenorphine is also capable of activating nociceptin/ orphanin FQ peptide (NOP) receptors (2) . The analgesic activity of buprenorphine is mediated by activation of -opioid receptors, and unaffected or reduced by activation of NOP receptors in rodents (3, 4) . Buprenorphine is now considered a broad spectrum analgesic, since it exhibits analgesic activity in a broad range of rodent models of acute and chronic pain including neuropathic pain (5, 6) and in neuropathic pain patients (1, 7) . Although the effectiveness of typical opioid analgesics such as morphine in neuropathic pain is controversial in general, the complex and unique pharmacological properties of buprenorphine including the ceiling effect on respiratory depression may provide some advantages over other -opioid agonists (1, 7). Most interestingly, there is recent evidence that coactivation of -opioid receptors and NOP receptors produces synergistic analgesia in primates (4). We thus hypothesized that the potent effect of buprenorphine on neuropathic pain might result from dual activation of -opioid receptors and NOP receptors. In the present study, we therefore evaluated the antihyperalgesic effect of buprenorphine in rats with spinal nerve injury-induced neuropathy and examined the roles of NOP receptors in addition to opioid receptors in the buprenorphine-induced antihyperalgesic and analgesic effects in neuropathic and naïve animals, respectively.
Male Wistar rats (7-week-old at the beginning of the study) were purchased from Japan SLC, Inc. (Shizuoka). All animals were used with approval by the Kinki University School of Pharmacy's Committee for the Care and Use of Laboratory Animals, and all experiments were performed according to the Guiding Principles approved by The Japanese Pharmacological Society. Mechanical nociceptive threshold was assessed by the paw pressure test, using an analgesia meter (MK-300; Muromachi Kikai Co., Tokyo), as described previously (8) (9) with some modifications (10).
The rat was used 14 -21 days after the operation. For intrathecal administration, a PE-10 tube was inserted into the lumber subarachnoid cavity from the space between the L5-L6 vertebrae in rats under pentobarbital anesthesia, as reported previously (8, 11) . Chemicals in a volume of 10 L were injected through the catheter, followed by flushing with 10 L of saline. (12, 13) . Naloxone was administered i.p. 25 min after i.p. buprenorphine because both spinal and supraspinal opioid receptors are known to mediate the analgesia caused by narcotic agents. All data are expressed as mean ± S.E.M. The data were analyzed by Student's ttest for two group comparisons or by Tukey's test for comparisons of three groups or more. A value of P < 0.05 was considered statistically significant.
In naïve rats, i.p. administration of buprenorphine at 50 g/kg, but not 20 g/kg, significantly elevated the mechanical nociceptive threshold (Fig. 1A) , an effect reversed by i.p. naloxone, an opioid receptor antagonist, at 1 mg/kg (data not shown). In the rats with L5 spinal nerve injury, the nociceptive threshold in the ipsilateral, but not contralateral, hindpaw decreased to approximately 60% of the baseline (Fig. 1B) . Buprenorphine at 0.5, 2, and 20 g/kg reversed the neuropathic hyperalgesia in a dose-dependent manner (Fig. 1B) . The AUC of the time-threshold curves for 2 h showed that the effective dose range of buprenorphine was 2 -20 g/kg in the ipsilateral hindpaw, while no significant effect of buprenorphine at the same doses was detected in the contralateral hindpaw ( Fig. 1: C, D) . On the other hand, morphine at 1 mg/kg produced a significant analgesic effect in both ipsilateral and contralateral hindpaws ( Fig. 1: C, D) . In the neuropathic rats, intrathecal admin- in the ipsilateral hindpaw ( Fig. 2A) . In contrast, intrathecal [N-Phe 1 ]nociceptin(1-13)NH 2 at the same dose did not affect the analgesic effect of i.p. buprenorphine at 50 g/kg in naïve rats (Fig. 2B) .
Our data clearly show that buprenorphine potently suppresses neuropathic hyperalgesia in a dose range, 2 -20 g/kg, that is lower than the minimal effective dose, 50 g/kg, in naïve rats. This increased analgesic potency of buprenorphine is not attributable to functional upregulation of opioid receptors in neuropathic rats, since the analgesic potency of morphine in the ipsilateral hindpaw of the neuropathic rats was similar to that in the contralateral hindpaw of the neuropathic rats (see Fig. 1: C, D) and also in the hindpaw of the naïve rats (data not shown). Therefore, acting points including NOP receptors other than opioid receptors should contribute to the antihyperalgesic effect of buprenoriphine in neuropathic rats. Actually, our study demonstrates that the antihyperalgesic effect of buprenorphine at the lower doses involves activation of both NOP receptors and opioid receptors in neuropathic rats, while the analgesic effect of buprenorphine at the higher doses is mediated predominantly by opioid receptor activation, but independent of NOP receptors, in naïve rats. Synergistic analgesia caused by coactivation of NOP receptors and -opioid receptors has been reported in primates (4) and rodents (12) . Interestingly, NOP receptors in the dorsal root ganglia (DRG) are upregulated in rats with neuropathy induced by partial sciatic nerve transection (14) . It has also been reported that intrathecal administration of NOP at 0.1 -10 g/rat had no effect on nociception in naïve rats, but suppressed neuropathic hyperalgesia in diabetic rats and in rats with mild chronic constrictive injury of the sciatic nerve (12) . These reports support the present evidence that both NOP receptors and -opioid receptors contribute to the antihyperalgesic activity of buprenorphine in neuropathic rats. In contrast, expression levels of NOP receptors in the DRG of the naïve rats might not be enough to mediate the buprenorphine analgesia. This notion may interpret why buprenorphine at 20 g/kg or lower doses did not exhibit significant analgesia in the hindpaw of the naïve rats (Fig. 1A) or in the contralateral hindpaw of the neuropathic rats (see Fig. 1D ). Given evidence for the therapeutic potential of mixed NOP receptor and -opioid receptor agonists in treatment of neuropathic pain (4, 12), we emphasize that buprenorphine is a useful analgesic for treating neuropathic pain. nociceptin(1-13)NH2 at the same dose was administered intrathecally 25 min after i.p. buprenorphine at 50 g/kg in naïve rats. Data show the mean ± S.E.M. for 6 -9 rats. The baseline threshold (g) was 162.2 ± 3.0, 170.5 ± 2.3, and 169.0 ± 4.5 in the left and right panels of (A) and in (B), respectively. *P < 0.05, **P < 0.01 vs. vehicle (V) + V; † P < 0.05, † † P < 0.01 vs. Bup + V.
